These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19216579)

  • 21. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human radiolabeled mass balance studies: objectives, utilities and limitations.
    Penner N; Klunk LJ; Prakash C
    Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG; Unger SE
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis.
    Mortishire-Smith RJ; O'Connor D; Castro-Perez JM; Kirby J
    Rapid Commun Mass Spectrom; 2005; 19(18):2659-70. PubMed ID: 16124034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites.
    Ma S; Chowdhury SK
    Bioanalysis; 2012 Mar; 4(5):501-10. PubMed ID: 22409549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL; Atrakchi A
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry.
    Ma S; Subramanian R
    J Mass Spectrom; 2006 Sep; 41(9):1121-39. PubMed ID: 16967439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid screening of glutathione-trapped reactive metabolites by linear ion trap mass spectrometry with isotope pattern-dependent scanning and postacquisition data mining.
    Ma L; Wen B; Ruan Q; Zhu M
    Chem Res Toxicol; 2008 Jul; 21(7):1477-83. PubMed ID: 18549250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 33. Algorithm for thorough background subtraction of high-resolution LC/MS data: application to obtain clean product ion spectra from nonselective collision-induced dissociation experiments.
    Zhang H; Grubb M; Wu W; Josephs J; Humphreys WG
    Anal Chem; 2009 Apr; 81(7):2695-700. PubMed ID: 19254033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitation of small molecules using high-resolution accurate mass spectrometers - a different approach for analysis of biological samples.
    Zhang NR; Yu S; Tiller P; Yeh S; Mahan E; Emary WB
    Rapid Commun Mass Spectrom; 2009 Apr; 23(7):1085-94. PubMed ID: 19263405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine.
    Zhang H; Ma L; He K; Zhu M
    J Mass Spectrom; 2008 Sep; 43(9):1191-200. PubMed ID: 18521834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma.
    Dear GJ; Roberts AD; Beaumont C; North SE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(2):182-90. PubMed ID: 19010088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From known knowns to known unknowns: predicting in vivo drug metabolites.
    Pelkonen O; Tolonen A; Korjamo T; Turpeinen M; Raunio H
    Bioanalysis; 2009 May; 1(2):393-414. PubMed ID: 21083174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combined approach to drug metabolism and toxicity assessment.
    Ekins S; Andreyev S; Ryabov A; Kirillov E; Rakhmatulin EA; Sorokina S; Bugrim A; Nikolskaya T
    Drug Metab Dispos; 2006 Mar; 34(3):495-503. PubMed ID: 16381662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.